Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
United Therapeutics Corporation v. Liquidia Technologies, Inc.
Case Number:
23-1805
Court:
Nature of Suit:
Companies
Sectors & Industries:
-
March 12, 2024
Federal Circuit Won't Reconsider Axing Tyvaso Patent
The full Federal Circuit on Tuesday declined to review a panel ruling from late last year that sided with a Patent Trial and Appeal Board decision that there was nothing patentable about a way of administering a blockbuster pulmonary hypertension drug.
-
December 20, 2023
Fed. Circ. Won't Touch Hypertension Drug Patent Ruling
The Federal Circuit decided Wednesday to leave untouched a ruling from the patent board that found there was nothing patentable about a purportedly new way of administering a blockbuster pulmonary hypertension drug, potentially shaking up drugmaker United Therapeutics' legal victory against a generic in Delaware federal court.